,docid,isValid,passage,passageid
0,AIMed.d3,False,"Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).",AIMed.d3.s30
1,AIMed.d3,False,"Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).",AIMed.d3.s30
2,AIMed.d3,False,"Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta-galactosidase (SA-beta-gal).",AIMed.d3.s30
3,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
4,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
5,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
6,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
7,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
8,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
9,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
10,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
11,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
12,AIMed.d3,False,"Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures.",AIMed.d3.s31
13,AIMed.d3,False,"The induced expression of p57, similar to p16, produces a senescent-like phenotype.",AIMed.d3.s32
14,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
15,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
16,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
17,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
18,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
19,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
20,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
21,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
22,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
23,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
24,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
25,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
26,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
27,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
28,AIMed.d3,False,"pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types.",AIMed.d3.s33
29,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
30,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
31,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
32,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
33,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
34,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
35,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
36,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
37,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
38,AIMed.d3,False,"We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence.",AIMed.d3.s34
39,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
40,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
41,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
42,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
43,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
44,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
45,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
46,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
47,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
48,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
49,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
50,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
51,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
52,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
53,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
54,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
55,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
56,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
57,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
58,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
59,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
60,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
61,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
62,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
63,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
64,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
65,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
66,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
67,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
68,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
69,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
70,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
71,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
72,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
73,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
74,AIMed.d3,False,"Analysis of p53, p21(CIP1), p15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells.",AIMed.d3.s35
75,AIMed.d4,False,Positive inotropic responses mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae.,AIMed.d4.s37
76,AIMed.d4,False,The aim of the present study was to determine possible inotropic effects mediated by endothelin ET(A) and ET(B) receptors in human myocardial trabeculae from the right atrium and the left ventricle.,AIMed.d4.s38
77,AIMed.d4,False,Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.,AIMed.d4.s40
78,AIMed.d4,False,Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.,AIMed.d4.s40
79,AIMed.d4,False,Endothelin-1 (ET-1) and ET-3 had a strong positive inotropic effect in all trabeculae.,AIMed.d4.s40
80,AIMed.d4,False,ET-1 was significantly more potent than ET-3 in both atrial (P < 0.001) and ventricular (P < 0.05) trabeculae.,AIMed.d4.s41
81,AIMed.d4,False,"Preincubation with the ET(A) receptor antagonist FR139317 (1 microM) decreased significantly (P < 0.005) the potency of ET- I in both atrial and ventricular trabeculae, without any significant changes in Emax (maximum effect obtained with an agonist).",AIMed.d4.s42
82,AIMed.d4,False,"The ET(B) receptor agonist IRL 1620 had a positive inotropic effect only in some trabeculae, and the ET(B) receptor antagonist BQ 788 (1 microM) almost completely blocked this effect.",AIMed.d4.s43
83,AIMed.d4,False,These results suggest that both ET(A) and ET(B) receptors mediate positive inotropic responses at both the atrial and ventricular level in the human heart.,AIMed.d4.s44
84,AIMed.d6,False,Apoptotic proteins. p53 and c-myc related pathways.,AIMed.d6.s50
85,AIMed.d6,False,c-Myc and p53 are two proteins that have critical roles in the regulation of apoptosis and the cell cycle.,AIMed.d6.s51
86,AIMed.d7,False,A comparative study of E-cadherin and stromelysin-3 expression in de novo and ex adenoma carcinoma of the colorectum.,AIMed.d7.s53
87,AIMed.d7,False,The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.,AIMed.d7.s56
88,AIMed.d7,False,The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.,AIMed.d7.s56
89,AIMed.d7,False,The purpose of the present comparative immunohistochemical study was to compare rates of cell adhesion molecule (E-cadherin) and protease [stromelysin-3 (ST-3)] expression in groups of de novo (n=64) and ex adenoma (n=42) lesions in order to see whether their more aggressive behavior is associated with decreased cell adhesion and increased protease expression.,AIMed.d7.s56
90,AIMed.d7,False,"The rates of extensive ST-3 expression and decreased E-cadherin expression were significantly higher in the de novo group (P=0.014 and 0.005, respectively).",AIMed.d7.s57
91,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88
92,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88
93,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88
94,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88
95,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88
96,AIMed.d11,False,"BACKGROUND: To elucidate the relationship between the expression of epidermal growth factor receptor family members (ErbB-1, neu/ErbB-2, ErbB-3, and ErbB-4) and tumor recurrence.",AIMed.d11.s88
97,AIMed.d11,False,"RESULTS: Using Cox univariate analysis, we determined that angiolymphatic tumor emboli and non-well-differentiated tumor cells were two significant conventional pathologic predictors of tumor recurrence, and that ErbB-1 and ErbB-3 were also significant predictors.",AIMed.d11.s90
98,AIMed.d13,False,"We performed cell-free in vitro infection of primary bone marrow derived CD34+ cells using semi-purified HHV8 and a mature IL-2 dependent T cell line, KIT 225, using highly concentrated viral stocks prepared from an infectious molecular clone of HTLV-1.",AIMed.d13.s109
99,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112
100,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112
101,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112
102,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112
103,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112
104,AIMed.d13,False,"Of these 400, interferon regulatory factor 4 (IRF4), cyclin B2, TBP-associated factor, eukaryotic elongation factor and pim 2 were up-regulated more than 3.5 fold.",AIMed.d13.s112
105,AIMed.d19,False,"Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.",AIMed.d19.s162
106,AIMed.d19,False,"Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.",AIMed.d19.s162
107,AIMed.d19,False,"Several genes are involved in this process, and two have been the focus of recent interest: the natural resistance-associated protein (NRAMP1) gene and the genes coding for the vitamin D receptor.",AIMed.d19.s162
108,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176
109,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176
110,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176
111,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176
112,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176
113,AIMed.d21,False,"Many of the same signaling molecules, including protein kinase C (PKC), tyrosine kinase, phosphatidylinositol 3-kinase (P13-K), and protein phosphatase, regulate the transporters for different neurotransmitters.",AIMed.d21.s176
114,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
115,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
116,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
117,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
118,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
119,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
120,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
121,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
122,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
123,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
124,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
125,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
126,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
127,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
128,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
129,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
130,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
131,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
132,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
133,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
134,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
135,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
136,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
137,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
138,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
139,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
140,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
141,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
142,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
143,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
144,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
145,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
146,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
147,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
148,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
149,AIMed.d24,False,"Comparison of messenger RNA gene expression of extracellular matrix proteins (procollagen I, collagenase, elastin, hyaluronic acid synthase 2, hyaluronidase, fibronectin, cd44, fibromodulin, and decorin) across cell passages (3, 4, 5, 6, 10, and 12 fornormal laminapropria and 3, 4, 5, 6, and 10 for tracheal scar) revealed varied growth patterns.",AIMed.d24.s200
150,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
151,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
152,AIMed.d28,True,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
153,AIMed.d28,True,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
154,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
155,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
156,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
157,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
158,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
159,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
160,AIMed.d28,True,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
161,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
162,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
163,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
164,AIMed.d28,False,"We have identified a new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor (hGITR), an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein [4].",AIMed.d28.s234
165,AIMed.d28,False,"The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].",AIMed.d28.s235
166,AIMed.d28,False,"The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].",AIMed.d28.s235
167,AIMed.d28,False,"The hGITRL gene mapped to chromosome 1q23, near the gene for the TNF homolog Fas/CD95 ligand [5].",AIMed.d28.s235
168,AIMed.d28,False,"We found hGITRL mRNA in several peripheral tissues, and detected hGITRL protein on cultured vascular endothelial cells.",AIMed.d28.s237
169,AIMed.d28,False,"The levels of hGITR mRNA in tissues were generally low; in peripheral blood T cells, however, antigen-receptor stimulation led to a substantial induction of hGITR transcripts.",AIMed.d28.s238
170,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
171,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
172,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
173,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
174,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
175,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
176,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
177,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
178,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
179,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
180,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
181,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
182,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
183,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
184,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
185,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
186,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
187,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
188,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
189,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
190,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
191,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
192,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
193,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
194,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
195,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
196,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
197,AIMed.d28,False,"Cotransfection of hGITRL and hGITR in embryonic kidney 293 cells activated the anti-apoptotic transcription factor NF-kappaB, via a pathway that appeared to involve TNFR-associated factor 2 (TRAF2) [7] and NF-kappaB-inducing kinase (NIK) [8].",AIMed.d28.s239
198,AIMed.d28,False,Cotransfection of hGITRL and hGITR in Jurkat T leukemia cells inhibited antigen-receptor-induced cell death.,AIMed.d28.s240
199,AIMed.d28,False,"Thus, hGITRL and hGITR may modulate T lymphocyte survival in peripheral tissues.",AIMed.d28.s241
200,AIMed.d31,False,A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.,AIMed.d31.s256
201,AIMed.d31,False,TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.,AIMed.d31.s257
202,AIMed.d31,False,TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.,AIMed.d31.s257
203,AIMed.d31,False,TR6 (decoy receptor 3 (DcR3)) is a new member of the tumor necrosis factor receptor (TNFR) family.,AIMed.d31.s257
204,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
205,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
206,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
207,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
208,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
209,AIMed.d31,True,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
210,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
211,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
212,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
213,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
214,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
215,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
216,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
217,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
218,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
219,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
220,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
221,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
222,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
223,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
224,AIMed.d31,False,"Here, we demonstrate that TR6 specifically binds two cellular ligands, LIGHT (herpes virus entry mediator (HVEM)-L) and Fas ligand (FasL/CD95L).",AIMed.d31.s262
225,AIMed.d31,False,TR6 inhibited LIGHT-induced cytotoxicity in HT29 cells.,AIMed.d31.s264
226,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
227,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
228,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
229,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
230,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
231,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
232,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
233,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
234,AIMed.d31,True,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
235,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
236,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
237,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
238,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
239,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
240,AIMed.d31,False,It has been shown that LIGHT triggers apoptosis of various tumor cells including HT29 cells that express both lymphotoxin beta receptor (LTbetaR) and HVEM/TR2 receptors.,AIMed.d31.s265
241,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
242,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
243,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
244,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
245,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
246,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
247,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
248,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
249,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
250,AIMed.d31,True,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
251,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
252,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
253,AIMed.d31,True,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
254,AIMed.d31,True,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
255,AIMed.d31,False,"Our data suggest that TR6 inhibits the interactions of LIGHT with HVEM/TR2 and LTbetaR, thereby suppressing LIGHT- mediated HT29 cell death.",AIMed.d31.s266
256,AIMed.d31,False,"Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.",AIMed.d31.s267
257,AIMed.d31,False,"Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.",AIMed.d31.s267
258,AIMed.d31,False,"Thus, TR6 may play a regulatory role for suppressing in FasL- and LIGHT-mediated cell death.",AIMed.d31.s267
259,AIMed.d34,False,Presenilin 1 (PS1) mutations account for the majority of early-onset dominant cases of familial Alzheimer's disease.,AIMed.d34.s285
260,AIMed.d34,True,"We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.",AIMed.d34.s288
261,AIMed.d34,True,"We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.",AIMed.d34.s288
262,AIMed.d34,False,"We report an interaction between the human PS1 or PS2 hydrophilic loop and Rab11, a small GTPase belonging to the Ras-related superfamily.",AIMed.d34.s288
263,AIMed.d34,True,"Interaction domains were mapped to codons 374-400 for PS1 and to codons 106-179 for Rab11, a region including the fourth GTP-binding domain.",AIMed.d34.s289
264,AIMed.d38,True,Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.,AIMed.d38.s320
265,AIMed.d38,False,"Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).",AIMed.d38.s321
266,AIMed.d38,False,"Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).",AIMed.d38.s321
267,AIMed.d38,False,"Previously, we mapped the novel CC chemokine myeloid progenitor inhibitory factor 2 (MPIF-2)/eotaxin-2 to chromosome 7q11.23 (Nomiyama, H., Osborne, L. R., Imai, T., Kusuda, J., Miura, R., Tsui, L.-C., and Yoshie, O. (1998) Genomics 49, 339-340).",AIMed.d38.s321
268,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323
269,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323
270,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323
271,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323
272,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323
273,AIMed.d38,False,"Prompted by this hypothesis, we analyzed the genomic region containing the gene for MPIF-2/eotaxin-2 (SCYA24) and have identified a novel CC chemokine termed eotaxin-3.",AIMed.d38.s323
274,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
275,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
276,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
277,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
278,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
279,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
280,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
281,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
282,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
283,AIMed.d38,False,The genes for MPIF-2/eotaxin-2 (SCYA24) and eotaxin-3 (SCYA26) are localized within a region of approximately 40 kilobases.,AIMed.d38.s324
284,AIMed.d38,False,Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.,AIMed.d38.s327
285,AIMed.d38,False,Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.,AIMed.d38.s327
286,AIMed.d38,False,Eotaxin-3 induced transient calcium mobilization specifically in CC chemokine receptor 3 (CCR3)-expressing L1.2 cells with an EC(50) of 3 nM.,AIMed.d38.s327
287,AIMed.d38,True,Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.,AIMed.d38.s328
288,AIMed.d38,True,Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.,AIMed.d38.s328
289,AIMed.d38,False,Eotaxin-3 competed the binding of (125)I-eotaxin to CCR3-expressing L1.2 cells with an IC(50) of 13 nM.,AIMed.d38.s328
290,AIMed.d38,True,"Collectively, eotaxin-3 is yet another functional ligand for CCR3.",AIMed.d38.s330
291,AIMed.d38,True,"The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.",AIMed.d38.s331
292,AIMed.d38,True,"The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.",AIMed.d38.s331
293,AIMed.d38,False,"The potency of eotaxin-3 as a CCR3 ligand seems, however, to be approximately 10-fold less than that of eotaxin.",AIMed.d38.s331
294,AIMed.d38,False,Identification of eotaxin-3 will further promote our understanding of the control of eosinophil trafficking and other CCR3-mediated biological phenomena.,AIMed.d38.s332
295,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
296,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
297,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
298,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
299,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
300,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
301,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
302,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
303,AIMed.d45,True,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
304,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
305,AIMed.d45,True,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
306,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
307,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
308,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
309,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
310,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
311,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
312,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
313,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
314,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
315,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
316,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
317,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
318,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
319,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
320,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
321,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
322,AIMed.d45,False,A mutant form of human interferon-gamma (IFN-gamma SC1) that binds one IFN-gamma receptor alpha chain (IFN-gamma R alpha) has been designed and characterized.,AIMed.d45.s390
323,AIMed.d45,False,IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.,AIMed.d45.s391
324,AIMed.d45,False,IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.,AIMed.d45.s391
325,AIMed.d45,False,IFN-gamma SC1 was derived by linking the two peptide chains of the IFN-gamma dimer by a seven-residue linker and changing His111 in the first chain to an aspartic acid residue.,AIMed.d45.s391
326,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392
327,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392
328,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392
329,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392
330,AIMed.d45,True,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392
331,AIMed.d45,False,Isothermal titration calorimetry shows that IFN-gamma SC1 forms a 1:1 complex with its high-affinity receptor (IFN-gamma R alpha) with an affinity of 27(+/- 9) nM.,AIMed.d45.s392
332,AIMed.d45,False,The crystal structure of IFN-gamma SC1 has been determined at 2.9 A resolution from crystals grown in 1.4 M citrate solutions at pH 7.6.,AIMed.d45.s393
333,AIMed.d45,False,Comparison of the wild-type receptor-binding domain and the Asp111-containing domain of IFN-gamma SC1 show that they are structurally equivalent but have very different electrostatic surface potentials.,AIMed.d45.s394
334,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
335,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
336,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
337,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
338,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
339,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
340,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
341,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
342,AIMed.d45,True,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
343,AIMed.d45,False,The AB loops of IFN-gamma SC1 adopt conformations similar to the ordered loops of IFN-gamma observed in the crystal structure of the IFN-gamma/IFN-gamma R alpha complex.,AIMed.d45.s396
344,AIMed.d45,False,"Thus, IFN-gamma R alpha binding does not result in a large conformational change in the AB loop as previously suggested.",AIMed.d45.s397
345,AIMed.d45,False,The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.,AIMed.d45.s398
346,AIMed.d45,False,The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.,AIMed.d45.s398
347,AIMed.d45,False,The structure also reveals the final six C-terminal amino acid residues of IFN-gamma SC1 (residues 253-258) that have not been observed in any other reported IFN-gamma structures.,AIMed.d45.s398
348,AIMed.d45,False,"Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.",AIMed.d45.s399
349,AIMed.d45,False,"Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.",AIMed.d45.s399
350,AIMed.d45,True,"Despite binding to only one IFN-gamma R alpha, IFN-gamma SC1 is biologically active in cell proliferation, MHC class I induction, and anti-viral assays.",AIMed.d45.s399
351,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
352,AIMed.d45,True,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
353,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
354,AIMed.d45,True,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
355,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
356,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
357,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
358,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
359,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
360,AIMed.d45,False,This suggests that one domain of IFN-gamma is sufficient to recruit IFN-gamma R alpha and IFN-gamma R beta into a complex competent for eliciting biological activity.,AIMed.d45.s400
361,AIMed.d45,False,The current data are consistent with the main role of the IFN-gamma dimer being to decrease the dissociation constant of IFN-gamma for its cellular receptors.,AIMed.d45.s401
362,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
363,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
364,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
365,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
366,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
367,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
368,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
369,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
370,AIMed.d55,True,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
371,AIMed.d55,False,"Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes.",AIMed.d55.s481
372,AIMed.d55,False,Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.,AIMed.d55.s482
373,AIMed.d55,False,Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.,AIMed.d55.s482
374,AIMed.d55,False,Liver-expressed chemokine (LEC)/CCL16 is a human CC chemokine selectively expressed in the liver.,AIMed.d55.s482
375,AIMed.d55,True,"At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.",AIMed.d55.s484
376,AIMed.d55,False,"At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.",AIMed.d55.s484
377,AIMed.d55,True,"At relatively high concentrations, LEC induced calcium mobilization and chemotaxis via CCR1 and CCR2.",AIMed.d55.s484
378,AIMed.d55,True,"LEC also induced calcium mobilization, but marginal chemotaxis via CCR5.",AIMed.d55.s485
379,AIMed.d55,True,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486
380,AIMed.d55,True,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486
381,AIMed.d55,True,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486
382,AIMed.d55,False,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486
383,AIMed.d55,False,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486
384,AIMed.d55,False,"Consistently, LEC was found to bind to CCR1, CCR2 and CCR5 with relatively low affinities.",AIMed.d55.s486
385,AIMed.d55,True,The binding of LEC to CCR8 was much less significant.,AIMed.d55.s487
386,AIMed.d55,True,"In spite of its binding to CCR5, LEC was unable to inhibit infection of an R5-type HIV-1 to activated human peripheral blood mononuclear cells even at high concentrations.",AIMed.d55.s488
387,AIMed.d55,True,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492
388,AIMed.d55,True,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492
389,AIMed.d55,True,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492
390,AIMed.d55,False,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492
391,AIMed.d55,False,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492
392,AIMed.d55,False,"Taken together, LEC is a new low-affinity functional ligand for CCR1, CCR2 and CCR5, and is constitutively expressed by liver parenchymal cells.",AIMed.d55.s492
393,AIMed.d62,False,The crystal structure of the homodimeric BB isoform of human recombinant platelet-derived growth factor (PDGF-BB) has been determined by X-ray analysis to 3.0 A resolution.,AIMed.d62.s541
394,AIMed.d66,False,"Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.",AIMed.d66.s562
395,AIMed.d66,True,"Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.",AIMed.d66.s564
396,AIMed.d66,False,"Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.",AIMed.d66.s564
397,AIMed.d66,True,"Cyclin E showed genetic interactions with the CDC28 gene, suggesting that it functioned at START by interacting with the CDC28 protein.",AIMed.d66.s564
398,AIMed.d66,False,Two human genes were identified that could interact with cyclin E to perform START in yeast containing a cdc28 mutation.,AIMed.d66.s565
399,AIMed.d66,False,"One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.",AIMed.d66.s566
400,AIMed.d66,False,"One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.",AIMed.d66.s566
401,AIMed.d66,False,"One was CDC2-HS, and the second was the human homolog of Xenopus CDK2.",AIMed.d66.s566
402,AIMed.d66,False,"Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.",AIMed.d66.s567
403,AIMed.d66,True,"Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.",AIMed.d66.s567
404,AIMed.d66,False,"Cyclin E produced in E. coli bound and activated the CDC2 protein in extracts from human G1 cells, and antibodies against cyclin E immunoprecipitated a histone H1 kinase from HeLa cells.",AIMed.d66.s567
405,AIMed.d66,True,"The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.",AIMed.d66.s568
406,AIMed.d66,True,"The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.",AIMed.d66.s568
407,AIMed.d66,False,"The interactions between cyclin E and CDC2, or CDK2, may be important at the G1 to S transition in human cells.",AIMed.d66.s568
408,AIMed.d72,False,A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product.,AIMed.d72.s609
409,AIMed.d72,False,"Tumour-suppressor genes, such as the human retinoblastoma susceptibility gene (Rb), are widely recognized as being vital in the control of cell growth and tumour formation.",AIMed.d72.s610
410,AIMed.d72,False,"How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.",AIMed.d72.s612
411,AIMed.d72,False,"How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.",AIMed.d72.s612
412,AIMed.d72,False,"How Rb acts to bring about this suppression is not clear but one clue is that the Rb protein forms complexes with the transforming oncoproteins of several DNA tumour viruses, and that two regions of Rb essential for such binding frequently contain mutations in tumour cells.",AIMed.d72.s612
413,AIMed.d72,False,"We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).",AIMed.d72.s614
414,AIMed.d72,False,"We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).",AIMed.d72.s614
415,AIMed.d72,False,"We report here the identification of one such human cellular Rb-associated protein of relative molecular mass 46,000 (46K) (RbAP46).",AIMed.d72.s614
416,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
417,AIMed.d72,True,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
418,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
419,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
420,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
421,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
422,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
423,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
424,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
425,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
426,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
427,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
428,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
429,AIMed.d72,True,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
430,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
431,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
432,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
433,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
434,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
435,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
436,AIMed.d72,False,"Two lines of evidence support the notion that RbAP46 and simian virus 40 T antigen have homologous Rb-binding properties: first, several mutated Rb proteins that failed to bind to T also did not associate with RbAP46; and second, both T antigen and T peptide (amino acids 101-118) were able to compete with RbAP46 for binding to Rb.",AIMed.d72.s615
437,AIMed.d72,True,The apparent targeting of the RbAP46-Rb interaction by oncoproteins of DNA tumour viruses strongly suggests that formation of this complex is functionally important.,AIMed.d72.s616
438,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
439,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
440,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
441,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
442,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
443,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
444,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
445,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
446,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
447,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
448,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
449,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
450,AIMed.d84,False,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
451,AIMed.d84,True,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
452,AIMed.d84,True,Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.,AIMed.d84.s711
453,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
454,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
455,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
456,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
457,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
458,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
459,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
460,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
461,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
462,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
463,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
464,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
465,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
466,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
467,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
468,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
469,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
470,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
471,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
472,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
473,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
474,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
475,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
476,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
477,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
478,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
479,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
480,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
481,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
482,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
483,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
484,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
485,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
486,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
487,AIMed.d84,False,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
488,AIMed.d84,True,"Using the yeast two-hybrid system, a genetic assay for studying protein-protein interactions, we have examined and compared the interaction of the insulin-like growth factor-I receptor (IGF-IR) and the insulin receptor (IR) with their two known substrates p52Shc and the insulin receptor substrate-1 (IRS-1).",AIMed.d84.s712
489,AIMed.d84,False,We also mapped the specific domains of the IGF-IR and p52Shc participating in these interactions.,AIMed.d84.s713
490,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
491,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
492,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
493,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
494,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
495,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
496,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
497,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
498,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
499,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
500,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
501,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
502,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
503,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
504,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
505,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
506,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
507,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
508,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
509,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
510,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
511,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
512,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
513,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
514,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
515,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
516,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
517,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
518,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
519,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
520,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
521,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
522,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
523,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
524,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
525,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
526,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
527,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
528,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
529,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
530,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
531,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
532,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
533,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
534,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
535,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
536,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
537,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
538,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
539,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
540,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
541,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
542,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
543,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
544,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
545,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
546,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
547,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
548,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
549,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
550,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
551,AIMed.d84,True,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
552,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
553,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
554,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
555,AIMed.d84,False,"Our findings can be summarized as follows: (i) the tyrosine kinase activity of the IGF-IR is essential for the interaction with p52Shc and IRS-1, (ii) p52Shc and IRS-1 bind to the IGF-IR in the NPEY-juxtamembrane motif, (iii) contrary to p52Shc, IRS-1 binds also to the major autophosphorylation sites (Tyr-1131, -1135, and -1136) of the IGF-IR, and (iv) the amino-terminal domain of p52Shc is required for its association with the IR and the IGF-IR.",AIMed.d84.s714
556,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
557,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
558,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
559,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
560,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
561,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
562,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
563,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
564,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
565,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
566,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
567,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
568,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
569,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
570,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
571,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
572,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
573,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
574,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
575,AIMed.d84,False,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
576,AIMed.d84,True,"We propose that (i) the IGF-IR and the IR share at least in part the same molecular mechanism underlying their interplay with their two substrates, p52Shc and IRS-1, and (ii) IRS-1 interacts with the IGF-IR in a fashion that is different from that used by p52Shc.",AIMed.d84.s715
577,AIMed.d84,False,"Finally, our data highlight the crucial role of the juxtamembrane domain in signaling by both the IR and the IGF-IR.",AIMed.d84.s716
578,AIMed.d86,False,"For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.",AIMed.d86.s728
579,AIMed.d86,False,"For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.",AIMed.d86.s728
580,AIMed.d86,False,"For the calibration, we used two sets of proteins, the Myc-Max-Mxi1 helix-loop-helix proteins, and wild-type and dimerization-defective versions of the lambda cI repressor.",AIMed.d86.s728
581,AIMed.d88,True,"Interaction of the protein nucleobindin with G alpha i2, as revealed by the yeast two-hybrid system.",AIMed.d88.s742
582,AIMed.d88,True,The specificity of intehraction between G alpha i2 and nucleobindin was confirmed by an in vitro binding assay using recombinant proteins.,AIMed.d88.s749
583,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750
584,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750
585,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750
586,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750
587,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750
588,AIMed.d88,False,Transfection of G alpha i2 and nucleobindin in COS cells increased G alpha i2 expression relative to cells transfected with G alpha i2 and mock vector.,AIMed.d88.s750
589,AIMed.d106,True,Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation.,AIMed.d106.s893
590,AIMed.d106,False,The Ras and Raf1 proto-oncogenes transduce extracellular signals that promote cell growth.,AIMed.d106.s894
591,AIMed.d106,True,We show here that Cdc25 phosphatase associates with raf1 in somatic mammalian cells and in meiotic frog oocytes.,AIMed.d106.s896
592,AIMed.d106,True,"Furthermore, Cdc25 phosphatase can be activated in vitro in a Raf1-dependent manner.",AIMed.d106.s897
593,AIMed.d106,False,We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.,AIMed.d106.s898
594,AIMed.d106,False,We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.,AIMed.d106.s898
595,AIMed.d106,False,We suggest that activation of the cell cycle by the Ras/Raf1 pathways might be mediated in part by Cdc25.,AIMed.d106.s898
596,AIMed.d107,True,A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase.,AIMed.d107.s899
597,AIMed.d107,False,Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.,AIMed.d107.s900
598,AIMed.d107,False,Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.,AIMed.d107.s900
599,AIMed.d107,False,Raf-1 is a serine/threonine protein kinase positioned downstream of Ras in the mitogen-activated protein kinase cascade.,AIMed.d107.s900
600,AIMed.d107,True,"Using a yeast two-hybrid strategy to identify other proteins that interact with and potentially regulate Raf-1, we isolated a clone encoding the carboxyl-terminal half of the G beta 2 subunit of heterotrimeric G-proteins.",AIMed.d107.s901
601,AIMed.d107,True,"In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).",AIMed.d107.s902
602,AIMed.d107,False,"In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).",AIMed.d107.s902
603,AIMed.d107,True,"In vitro, purified G beta gamma subunits specifically bound to a GST fusion protein encoding amino acids 1-330 of Raf-1 (Raf/330).",AIMed.d107.s902
604,AIMed.d107,False,Binding assays with truncation mutants of GST-Raf indicate that the region located between amino acids 136 and 239 is a primary determinant for interaction with G beta gamma.,AIMed.d107.s903
605,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
606,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
607,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
608,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
609,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
610,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
611,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
612,AIMed.d107,True,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
613,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
614,AIMed.d107,True,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
615,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
616,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
617,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
618,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
619,AIMed.d107,False,"In competition experiments, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK) blocked the binding of G beta gamma to Raf/330; however, the Raf-1-binding proteins, Ras and 14-3-3, had no effect.",AIMed.d107.s904
620,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905
621,AIMed.d107,True,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905
622,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905
623,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905
624,AIMed.d107,True,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905
625,AIMed.d107,False,"Scatchard analysis of in vitro binding between Raf/330 and G beta gamma revealed an affinity of interaction (Kd = 163 +/- 36 nM), similar to that seen between G beta gamma and beta ARK (Kd = 87 +/- 24 nM).",AIMed.d107.s905
626,AIMed.d107,False,"The formation of native heterotrimeric G alpha beta gamma complexes, as measured by pertussis toxin ADP-ribosylation of G alpha, could be disrupted by increasing amounts of Raf/330, with an EC50 of approximately 200 nM, in close agreement with the estimated binding affinity.",AIMed.d107.s906
627,AIMed.d107,False,In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.,AIMed.d107.s907
628,AIMed.d107,False,In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.,AIMed.d107.s907
629,AIMed.d107,True,In vivo complexes of Raf-1 and G beta gamma were isolated from human embryonic kidney 293-T cells transfected with epitope-tagged G beta 2.,AIMed.d107.s907
630,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930
631,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930
632,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930
633,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930
634,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930
635,AIMed.d111,False,Mutagenesis of the regulatory subunit (RII beta) of cAMP-dependent protein kinase II beta reveals hydrophobic amino acids that are essential for RII beta dimerization and/or anchoring RII beta to the cytoskeleton.,AIMed.d111.s930
636,AIMed.d111,False,In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).,AIMed.d111.s931
637,AIMed.d111,False,In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).,AIMed.d111.s931
638,AIMed.d111,False,In neurons cAMP-dependent protein kinase II beta (PKAII beta) is sequestered in the dendritic cytoskeleton because the regulatory subunit (RII beta) of the enzyme is tightly bound by A Kinase Anchor Proteins (AKAPs).,AIMed.d111.s931
639,AIMed.d111,True,The prototypic neuronal anchor protein AKAP75 has a COOH-terminal 22-residue RII beta binding (tethering) site.,AIMed.d111.s932
640,AIMed.d111,True,"Mutagenesis, recombinant protein expression, and physicochemical characterization were used to investigate the structural basis for the homodimerization and AKAP75 binding activities of RII beta.",AIMed.d111.s934
641,AIMed.d111,False,Substitution of Ala for Leu13 or Phe36 generates monomeric RII beta subunits that cannot bind AKAP75.,AIMed.d111.s936
642,AIMed.d111,False,The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.,AIMed.d111.s937
643,AIMed.d111,False,The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.,AIMed.d111.s937
644,AIMed.d111,False,The results are not due to general misfolding since mutant RII beta monomers bind cAMP and inhibit the catalytic subunit of PKAII beta with the same affinity and efficacy as wild-type RII beta dimers.,AIMed.d111.s937
645,AIMed.d111,True,"Evidently, large hydrophobic side chains of Leu13 and Phe36 play pivotal roles in stabilizing RII beta-RII beta interactions.",AIMed.d111.s939
646,AIMed.d111,False,A secondary consequence of destabilizing RII beta dimers is the loss of intracellular targeting/anchoring capacity because monomers fail to bind AKAP75.,AIMed.d111.s940
647,AIMed.d111,True,Other NH2-terminal residues directly modulate the affinity of RII beta dimers for the AKAP75 tethering site.,AIMed.d111.s941
648,AIMed.d111,True,Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.,AIMed.d111.s942
649,AIMed.d111,False,Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.,AIMed.d111.s942
650,AIMed.d111,False,Replacement of Val20-Leu21 with Ala-Ala produced a dimeric RII beta protein that binds AKAP75 approximately 4% as avidly as wild-type RII beta.,AIMed.d111.s942
651,AIMed.d133,True,JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.,AIMed.d133.s1132
652,AIMed.d133,False,JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.,AIMed.d133.s1132
653,AIMed.d133,False,JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.,AIMed.d133.s1132
654,AIMed.d133,False,The ultraviolet (UV) response of mammalian cells is characterized by a rapid and selective increase in gene expression mediated by AP-1 and NF-kappa B.,AIMed.d133.s1133
655,AIMed.d133,False,"The effect on AP-1 transcriptional activity results, in part, from enhanced phosphorylation of the c-Jun NH2-terminal activation domain.",AIMed.d133.s1134
656,AIMed.d133,False,"Here, we describe the molecular cloning and characterization of JNK1, a distant relative of the MAP kinase group that is activated by dual phosphorylation at Thr and Tyr during the UV response.",AIMed.d133.s1135
657,AIMed.d133,True,"Significantly, Ha-Ras partially activates JNK1 and potentiates the activation caused by UV.",AIMed.d133.s1136
658,AIMed.d133,True,JNK1 binds to the c-Jun transactivation domain and phosphorylates it on Ser-63 and Ser-73.,AIMed.d133.s1137
659,AIMed.d134,False,B61 is a ligand for the ECK receptor protein-tyrosine kinase.,AIMed.d134.s1140
660,AIMed.d134,True,B61 is a ligand for the ECK receptor protein-tyrosine kinase.,AIMed.d134.s1140
661,AIMed.d134,False,B61 is a ligand for the ECK receptor protein-tyrosine kinase.,AIMed.d134.s1140
662,AIMed.d134,False,A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.,AIMed.d134.s1141
663,AIMed.d134,False,A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.,AIMed.d134.s1141
664,AIMed.d134,False,A protein ligand for the ECK receptor protein-tyrosine kinase has been isolated by using the extracellular domain (ECK-X) of the receptor as an affinity reagent.,AIMed.d134.s1141
665,AIMed.d134,False,"Subsequently, supernatants from selected cell lines were fractionated directly by receptor affinity chromatography, resulting in the single-step purification of B61, a protein previously identified as the product of an early response gene induced by tumour necrosis factor-alpha.",AIMed.d134.s1143
666,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144
667,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144
668,AIMed.d134,True,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144
669,AIMed.d134,True,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144
670,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144
671,AIMed.d134,False,"We report here that recombinant B61 induces autophosphorylation of ECK in intact cells, consistent with B61 being an authentic ligand for ECK.",AIMed.d134.s1144
672,AIMed.d134,False,"ECK is a member of a large orphan receptor protein-tyrosine kinase family headed by EPH, and we suggest that ligands for other members of this family will be related to B61, and can be isolated in the same way.",AIMed.d134.s1145
673,AIMed.d140,True,"Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.",AIMed.d140.s1180
674,AIMed.d140,False,"We used the interaction trap, a yeast genetic selection for interacting proteins, to isolate human cyclin-dependent kinase interactor 1 (Cdi1).",AIMed.d140.s1181
675,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
676,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
677,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
678,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
679,AIMed.d140,True,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
680,AIMed.d140,True,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
681,AIMed.d140,True,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
682,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
683,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
684,AIMed.d140,False,"In yeast, Cdi1 interacts with cyclin-dependent kinases, including human Cdc2, Cdk2, and Cdk3, but not with Cdk4.",AIMed.d140.s1182
685,AIMed.d140,True,"In HeLa cells, Cdi1 is expressed at the G1 to S transition, and the protein forms stable complexes with Cdk2.",AIMed.d140.s1183
686,AIMed.d140,False,Overexpression of wild-type Cdi1 delays progression through the cell cycle in yeast and HeLa cells; delay is dependent on Cdi1 phosphatase activity.,AIMed.d140.s1186
687,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262
688,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262
689,AIMed.d149,True,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262
690,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262
691,AIMed.d149,True,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262
692,AIMed.d149,False,The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling.,AIMed.d149.s1262
693,AIMed.d149,False,"GRB2, a small protein comprising one SH2 domain and two SH3 domains, represents the human homologue of the Caenorhabditis elegans protein, sem-5.",AIMed.d149.s1263
694,AIMed.d149,False,Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.,AIMed.d149.s1264
695,AIMed.d149,False,Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.,AIMed.d149.s1264
696,AIMed.d149,False,Both GRB2 and sem-5 have been implicated in a highly conserved mechanism that regulates p21ras signalling by receptor tyrosine kinases.,AIMed.d149.s1264
697,AIMed.d149,False,"In this report we show that in response to insulin, GRB2 forms a stable complex with two tyrosine-phosphorylated proteins.",AIMed.d149.s1265
698,AIMed.d149,False,"One protein is the major insulin receptor substrate IRS-1 and the second is the SH2 domain-containing oncogenic protein, Shc.",AIMed.d149.s1266
699,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
700,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
701,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
702,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
703,AIMed.d149,True,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
704,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
705,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
706,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
707,AIMed.d149,True,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
708,AIMed.d149,False,The interactions between GRB2 and these two proteins require ligand activation of the insulin receptor and are mediated by the binding of the SH2 domain of GRB2 to phosphotyrosines on both IRS-1 and Shc.,AIMed.d149.s1267
709,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
710,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
711,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
712,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
713,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
714,AIMed.d149,True,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
715,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
716,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
717,AIMed.d149,False,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
718,AIMed.d149,True,"Although GRB2 associates with IRS-1 and Shc, it is not tyrosine-phosphorylated after insulin stimulation, implying that GRB2 is not a substrate for the insulin receptor.",AIMed.d149.s1268
719,AIMed.d149,False,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269
720,AIMed.d149,False,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269
721,AIMed.d149,True,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269
722,AIMed.d149,False,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269
723,AIMed.d149,True,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269
724,AIMed.d149,True,"Furthermore, we have identified a short sequence motif (YV/IN) present in IRS-1, EGFR and Shc, which specifically binds the SH2 domain of GRB2 with high affinity.",AIMed.d149.s1269
725,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270
726,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270
727,AIMed.d149,True,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270
728,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270
729,AIMed.d149,True,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270
730,AIMed.d149,False,"Interestingly, both GRB2 and phosphatidylinositol-3 (PI-3) kinase can simultaneously bind distinct tyrosine phosphorylated regions on the same IRS-1 molecule, suggesting a mechanism whereby IRS-1 could provide the core for a large signalling complex.",AIMed.d149.s1270
731,AIMed.d149,True,We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.,AIMed.d149.s1271
732,AIMed.d149,True,We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.,AIMed.d149.s1271
733,AIMed.d149,False,We propose a model whereby insulin stimulation leads to formation of multiple protein--protein interactions between GRB2 and the two targets IRS-1 and Shc.,AIMed.d149.s1271
734,AIMed.d155,False,"The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.",AIMed.d155.s1316
735,AIMed.d155,False,"The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.",AIMed.d155.s1316
736,AIMed.d155,False,"The general transcription factor TFIID nucleates initiation complex formation through direct core promoter binding, commits promoters within chromatin to transcription, and mediates the action of transcriptional activators, a phenomenon that may correlate with enhanced TFIID recruitment or conformational changes in TFIID-promoter complexes.",AIMed.d155.s1316
737,AIMed.d155,False,"Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.",AIMed.d155.s1317
738,AIMed.d155,False,"Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.",AIMed.d155.s1317
739,AIMed.d155,False,"Molecular studies of the multiprotein TFIID complex have identified a primary TATA binding subunit (TBP), TBP-associated factors (TAFs) that interact with and mediate the function of activators and intersubunit interactions but have yielded relatively little insight into the structural organization of the complex or the actual mechanism of transcriptional activation.",AIMed.d155.s1317
740,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318
741,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318
742,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318
743,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318
744,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318
745,AIMed.d155,False,"Here we present biochemical evidence for the structural relevance of histone homologies in the human TFIID subunits hTAF80, hTAF31 and hTAF20/15.",AIMed.d155.s1318
746,AIMed.d155,False,"Together with analyses of native TFIID complexes and accompanying crystallographic studies, the results suggest that there is a histone octamer-like TAF complex within TFIID.",AIMed.d155.s1319
747,AIMed.d156,True,IRAK: a kinase associated with the interleukin-1 receptor.,AIMed.d156.s1320
748,AIMed.d156,False,The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).,AIMed.d156.s1321
749,AIMed.d156,True,The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).,AIMed.d156.s1321
750,AIMed.d156,True,The pleiotropic biological activities of interleukin-1 (IL-1) are mediated by its type I receptor (IL-1RI).,AIMed.d156.s1321
751,AIMed.d156,False,"When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).",AIMed.d156.s1322
752,AIMed.d156,False,"When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).",AIMed.d156.s1322
753,AIMed.d156,False,"When the ligand binds, IL-1RI initiates a signaling cascade that results in the activation of the transcription regulator nuclear factor kappa B (NF-kappa B).",AIMed.d156.s1322
754,AIMed.d156,False,"A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.",AIMed.d156.s1323
755,AIMed.d156,False,"A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.",AIMed.d156.s1323
756,AIMed.d156,False,"A protein kinase designated IRAK (IL-1 receptor-associated kinase) was purified, and its complementary DNA was molecularly cloned.",AIMed.d156.s1323
757,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324
758,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324
759,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324
760,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324
761,AIMed.d156,True,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324
762,AIMed.d156,False,"When human embryonic kidney cells (cell line 293) over-expressing IL-1RI or HeLa cells were exposed to IL-1, IRAK rapidly associated with the IL-1RI complex and was phosphorylated.",AIMed.d156.s1324
763,AIMed.d156,False,"The primary amino acid sequence of IRAK shares similarity with that of pelle,a protein kinase that is essential for the activation of a NF-kappa B homolog in Drosophila.",AIMed.d156.s1325
764,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
765,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
766,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
767,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
768,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
769,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
770,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
771,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
772,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
773,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
774,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
775,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
776,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
777,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
778,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
779,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
780,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
781,AIMed.d170,True,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
782,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
783,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
784,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
785,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
786,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
787,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
788,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
789,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
790,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
791,AIMed.d170,False,"The phagocyte NADPH oxidase is a complex of membrane cytochrome b558 (comprised of subunits p22-phox and gp91-phox) and three cytosol proteins (p47-phox, p67-phox, and p21rac) that translocate to membrane and bind to cytochrome b558.",AIMed.d170.s1438
792,AIMed.d170,True,"This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.",AIMed.d170.s1439
793,AIMed.d170,False,"This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.",AIMed.d170.s1439
794,AIMed.d170,False,"This is the first report to demonstrate that two of cytosolic components of cytochrome b558, p47-phox binding to p67-phox each other.",AIMed.d170.s1439
795,AIMed.d178,True,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508
796,AIMed.d178,False,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508
797,AIMed.d178,False,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508
798,AIMed.d178,True,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508
799,AIMed.d178,True,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508
800,AIMed.d178,False,"In vitro and in nonproliferating cells, p27 associates with and inhibits cyclin/cycin-dependent kinase (CDK) holoenzymes containing either CDK4, CDK6, or CDK2.",AIMed.d178.s1508
801,AIMed.d178,False,"Although many different types of proliferating cells contain p27 protein, neither the interactions of p27 with cyclin/CDK complexes nor the consequences of this interaction during the mitotic cycle have been fully explored.",AIMed.d178.s1509
802,AIMed.d178,True,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511
803,AIMed.d178,False,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511
804,AIMed.d178,False,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511
805,AIMed.d178,True,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511
806,AIMed.d178,True,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511
807,AIMed.d178,False,"In addition, p27 associates with three different CDKs: CDK2, CDK4, and CDK6.",AIMed.d178.s1511
808,AIMed.d178,False,"Furthermore, the amount of p27 is significantly lower than the amount of cyclin D3 in these cells.",AIMed.d178.s1512
809,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
810,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
811,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
812,AIMed.d178,True,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
813,AIMed.d178,True,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
814,AIMed.d178,True,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
815,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
816,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
817,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
818,AIMed.d178,False,"The amount of CDK4 and CDK6 associated with p27 does not change in a cell cycle-dependent fashion; in contrast, the amount of CDK2 associated with p27 is lowest in early G1 cells and increases to a maximum in mid-G1 phase, reaching a steady-state level in late G1-phase cells.",AIMed.d178.s1513
819,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516
820,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516
821,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516
822,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516
823,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516
824,AIMed.d178,False,"The substrate specificity, the expression pattern of this kinase, and the ability to deplete 50% of this kinase activity with a CDK6-specific antibody suggest that the CDK6 protein mediates, in part, the p27-associated Rb-kinase activity.",AIMed.d178.s1516
825,AIMed.d178,True,"In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.",AIMed.d178.s1517
826,AIMed.d178,False,"In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.",AIMed.d178.s1517
827,AIMed.d178,False,"In contrast, p27 complexes containing CDK2 are incapable of phosphorylating histone H1.",AIMed.d178.s1517
828,AIMed.d178,False,These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.,AIMed.d178.s1518
829,AIMed.d178,False,These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.,AIMed.d178.s1518
830,AIMed.d178,False,These data are consistent with a model wherein cyclin D/CDK complexes sequester the CDK2-dependent kinase inhibitory activity of p27.,AIMed.d178.s1518
831,AIMed.d181,True,Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.,AIMed.d181.s1538
832,AIMed.d181,True,The core domain contains the sequence-specific DNA binding activity and the in vitro 53BP2 protein binding activity of p53.,AIMed.d181.s1540
833,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541
834,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541
835,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541
836,AIMed.d181,True,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541
837,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541
838,AIMed.d181,False,"The crystal structure of the p53 core domain bound to the 53BP2 protein, which contains an SH3 (Src homology 3) domain and four ankyrin repeats, revealed that (i) the SH3 domain binds the L3 loop of p53 in a manner distinct from that of previously characterized SH3-polyproline peptide complexes, and (ii) an ankyrin repeat, which forms an L-shaped structure consisting of a beta hairpin and two alpha helices, binds the L2 loop of p53.",AIMed.d181.s1541
839,AIMed.d181,True,The structure of the complex shows that the 53BP2 binding site on the p53 core domain consists of evolutionarily conserved regions that are frequently mutated in cancer and that it overlaps the site of DNA binding.,AIMed.d181.s1542
840,AIMed.d181,True,The six most frequently observed p53 mutations disrupt 53BP2 binding in vitro.,AIMed.d181.s1543
841,AIMed.d181,False,The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.,AIMed.d181.s1544
842,AIMed.d181,False,The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.,AIMed.d181.s1544
843,AIMed.d181,True,The structure provides evidence that the 53BP2-p53 complex forms in vivo and may have a critical role in the p53 pathway of tumor suppression.,AIMed.d181.s1544
844,AIMed.d186,False,cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.,AIMed.d186.s1579
845,AIMed.d186,False,cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.,AIMed.d186.s1579
846,AIMed.d186,False,cDNA cloning and characterization of the human interleukin 13 receptor alpha chain.,AIMed.d186.s1579
847,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580
848,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580
849,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580
850,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580
851,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580
852,AIMed.d186,False,We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13Ralpha).,AIMed.d186.s1580
853,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
854,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
855,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
856,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
857,AIMed.d186,True,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
858,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
859,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
860,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
861,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
862,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
863,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
864,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
865,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
866,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
867,AIMed.d186,False,"Only weak IL-13 binding activity was found in cells transfected with only IL-13Ralpha; however, the combination of both IL-13Ralpha and IL-4Ralpha resulted in substantial binding activity, with a Kd of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor.",AIMed.d186.s1582
868,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
869,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
870,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
871,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
872,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
873,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
874,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
875,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
876,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
877,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
878,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
879,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
880,AIMed.d186,True,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
881,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
882,AIMed.d186,False,"Whereas IL-13Ralpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gammac) for IL-4 signaling, it could not replace the function of gammac in allowing enhanced IL-2 binding activity.",AIMed.d186.s1583
883,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584
884,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584
885,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584
886,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584
887,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584
888,AIMed.d186,False,"Nevertheless, the overall size and length of the cytoplasmic domain of IL-13Ralpha and gammac are similar, and like gammac, IL-13Ralpha is located on chromosome X.",AIMed.d186.s1584
889,AIMed.d188,False,SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein.,AIMed.d188.s1595
890,AIMed.d188,False,"In an unbiased search for potential coactivators of SREBP, we isolated a protein of 265 kD from HeLa cells that directly bound SREBP-1 and SREBP-2.",AIMed.d188.s1598
891,AIMed.d188,False,"Peptide sequencing and Western blot analysis established that the 265-kD protein was CBP (CREB-binding protein),a recently identified transcriptional coactivator.",AIMed.d188.s1599
892,AIMed.d188,False,The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).,AIMed.d188.s1600
893,AIMed.d188,False,The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).,AIMed.d188.s1600
894,AIMed.d188,False,The putative activation domain of SREBP was shown to bind specifically to amino-terminal domains of recombinant CBP and p300 (a CBP-related protein).,AIMed.d188.s1600
895,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
896,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
897,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
898,AIMed.d189,True,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
899,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
900,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
901,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
902,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
903,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
904,AIMed.d189,False,"Associations of UBE2I with RAD52, UBL1, p53, and RAD51 proteins in a yeast two-hybrid system.",AIMed.d189.s1603
905,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
906,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
907,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
908,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
909,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
910,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
911,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
912,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
913,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
914,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
915,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
916,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
917,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
918,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
919,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
920,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
921,AIMed.d189,True,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
922,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
923,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
924,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
925,AIMed.d189,False,"Using the human RAD52 protein as the ""bait"" in a yeast two-hybrid system, we have identified a human homolog of yeast UBC9, designated UBE2I, that interacts with RAD52, RAD51, p53, and a ubiquitin-like protein UBL1.",AIMed.d189.s1606
926,AIMed.d189,False,"These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.",AIMed.d189.s1607
927,AIMed.d189,False,"These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.",AIMed.d189.s1607
928,AIMed.d189,False,"These interactions are UBE2I-specific, since another DNA repair-related ubiquitin-conjugating enzyme, RAD6 (UBC2), does not interact with these proteins.",AIMed.d189.s1607
929,AIMed.d189,True,The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.,AIMed.d189.s1608
930,AIMed.d189,False,The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.,AIMed.d189.s1608
931,AIMed.d189,False,The interaction of UBE2I with RAD52 is mediated by RAD52's self-association region.,AIMed.d189.s1608
932,AIMed.d189,False,"These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.",AIMed.d189.s1609
933,AIMed.d189,False,"These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.",AIMed.d189.s1609
934,AIMed.d189,False,"These results suggest that the RAD52-dependent processes, cell cycle control, p53-mediated pathway(s), and ubiquitination interact through human UBE2I.",AIMed.d189.s1609
935,AIMed.d191,False,"We now find that HIV-1 begins reverse transcription much more efficiently in DCs than T cells, even though T cells have higher levels of CD4 and gp120 binding.",AIMed.d191.s1623
936,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631
937,AIMed.d191,True,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631
938,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631
939,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631
940,AIMed.d191,True,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631
941,AIMed.d191,False,RANTES interacts with CCR5 and SDF-1 with CXCR4 receptors.,AIMed.d191.s1631
942,AIMed.d191,False,DCs express more CCR5 and CXCR4 mRNA than T cells.,AIMed.d191.s1633
943,AIMed.d200,True,"Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells.",AIMed.d200.s1722
944,AIMed.d200,False,Interactions with human PARP and mouse replication factor 1a were confirmed using glutathione transferase-tagged cDNAs.,AIMed.d200.s1725
945,AIMed.d200,True,A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.,AIMed.d200.s1726
946,AIMed.d201,False,Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.,AIMed.d201.s1727
947,AIMed.d201,False,Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.,AIMed.d201.s1727
948,AIMed.d201,False,Hepatitis B virus X protein is a transcriptional modulator that communicates with transcription factor IIB and the RNA polymerase II subunit 5.,AIMed.d201.s1727
949,AIMed.d201,False,Hepatitis B virus X protein (HBx) transactivates viral and cellular genes through a wide variety of cis-elements.,AIMed.d201.s1728
950,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730
951,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730
952,AIMed.d201,True,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730
953,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730
954,AIMed.d201,True,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730
955,AIMed.d201,False,"Our finding that HBx directly interacts with RNA polymerase II subunit 5 (RPB5), a common subunit of RNA polymerases, implies that HBx directly modulates the function of RNA polymerase (Cheong, J. H., Yi, M., Lin, Y., and Murakami, S. (1995) EMBO J. 14, 142-150).",AIMed.d201.s1730
956,AIMed.d201,False,"In this context, we examined the possibility that HBx and RPB5 interact with other general transcription factors.",AIMed.d201.s1731
957,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732
958,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732
959,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732
960,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732
961,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732
962,AIMed.d201,False,"HBx and RPB5 specifically bound to transcription factor IIB (TFIIB) in vitro, both of which were detected by either far-Western blotting or the glutathione S-transferase-resin pull-down assay.",AIMed.d201.s1732
963,AIMed.d201,False,"Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.",AIMed.d201.s1733
964,AIMed.d201,False,"Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.",AIMed.d201.s1733
965,AIMed.d201,True,"Delineation of the binding regions of these three proteins revealed that HBx, RPB5, and TFIIB each has two binding regions for the other two proteins.",AIMed.d201.s1733
966,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
967,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
968,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
969,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
970,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
971,AIMed.d201,True,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
972,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
973,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
974,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
975,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
976,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
977,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
978,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
979,AIMed.d201,True,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
980,AIMed.d201,False,"Some HBx substitution mutants, which had severely impaired transacting activity, exhibited reduced binding affinity with either TFIIB or RPB5 in a mutually exclusive manner, suggesting that HBx transactivation requires the interactions of both RPB5 and TFIIB.",AIMed.d201.s1735
981,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736
982,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736
983,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736
984,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736
985,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736
986,AIMed.d201,False,These results indicated that HBx is a novel virus modulator that facilitates transcriptional initiation by stabilizing the association between RNA polymerase and TFIIB through communication with RPB5 and TFIIB.,AIMed.d201.s1736
987,AIMed.d203,False,A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist.,AIMed.d203.s1746
988,AIMed.d203,False,"Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).",AIMed.d203.s1747
989,AIMed.d203,False,"Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).",AIMed.d203.s1747
990,AIMed.d203,False,"Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1).",AIMed.d203.s1747
991,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
992,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
993,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
994,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
995,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
996,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
997,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
998,AIMed.d203,True,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
999,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1000,AIMed.d203,True,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1001,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1002,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1003,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1004,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1005,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1006,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1007,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1008,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1009,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1010,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1011,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1012,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1013,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1014,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1015,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1016,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1017,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1018,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1019,AIMed.d203,True,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1020,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1021,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1022,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1023,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1024,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1025,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1026,AIMed.d203,False,Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2).,AIMed.d203.s1748
1027,AIMed.d203,False,Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.,AIMed.d203.s1750
1028,AIMed.d203,False,Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.,AIMed.d203.s1750
1029,AIMed.d203,True,Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA.,AIMed.d203.s1750
1030,AIMed.d203,False,"A region that is important for biological function in IL-1beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex.",AIMed.d203.s1754
1031,AIMed.d210,True,Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.,AIMed.d210.s1817
1032,AIMed.d210,False,Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.,AIMed.d210.s1817
1033,AIMed.d210,False,Cross-family interaction between the bHLHZip USF and bZip Fra1 proteins results in down-regulation of AP1 activity.,AIMed.d210.s1817
1034,AIMed.d210,False,"To further examine the function of the bHLHZip protein, USF, we screened for cellular proteins which could directly interact with USF using the yeast two-hybrid system.",AIMed.d210.s1819
1035,AIMed.d210,True,"A bZip protein, Fra1, was found to efficiently interact with USF.",AIMed.d210.s1820
1036,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1037,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1038,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1039,AIMed.d210,True,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1040,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1041,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1042,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1043,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1044,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1045,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1046,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1047,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1048,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1049,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1050,AIMed.d210,False,"USF specifically interacts with Fra1 but not with other closely related family members, c-Fos, Fra2, FosB, or with c-Jun.",AIMed.d210.s1821
1051,AIMed.d210,True,Both the bHLHZip and the N-terminal regions of Fra1 are required for efficient interaction with USF.,AIMed.d210.s1822
1052,AIMed.d210,True,In vivo association between USF and Fra1 has been demonstrated by co-immunoprecipitation.,AIMed.d210.s1823
1053,AIMed.d210,False,Expression of exogenous USF led to a decrease in AP1-dependent transcription in F9 cells.,AIMed.d210.s1824
1054,AIMed.d210,False,Co-expression of exogenous Fra1 restored the AP1 activity in a dose-dependent manner.,AIMed.d210.s1825
1055,AIMed.d210,True,These data show that USF and Fra1 physically and functionally interact demonstrating that cross-talk occurs between factors of distantly related transcription families.,AIMed.d210.s1826
1056,AIMed.d212,True,Interaction between ATM protein and c-Abl in response to DNA damage.,AIMed.d212.s1835
1057,AIMed.d212,False,"The gene mutated in the autosomal recessive disorder ataxia telangiectasia (AT), designated ATM (for 'AT mutated'), is a member of a family of phosphatidylinositol-3-kinase-like enzymes that are involved in cell-cycle control, meiotic recombination, telomere length monitoring and DNA-damage response.",AIMed.d212.s1836
1058,AIMed.d212,False,"Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.",AIMed.d212.s1838
1059,AIMed.d212,True,"Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.",AIMed.d212.s1838
1060,AIMed.d212,False,"Because cells lacking the protein tyrosine kinase c-Abl are also defective in radiation-induced G1 arrest, we investigated the possibility that ATM might interact with c-Abl in response to radiation damage.",AIMed.d212.s1838
1061,AIMed.d212,True,Here we show that ATM binds c-Abl constitutively in control cells but not in AT cells.,AIMed.d212.s1839
1062,AIMed.d212,True,"Our results demonstrate that the SH3 domain of c-Abl interacts with a DPAPNPPHFP motif (residues 1,373-1,382) of ATM.",AIMed.d212.s1840
1063,AIMed.d212,True,These findings indicate that ATM is involved in the activation of c-Abl by DNA damage and this interaction may in part mediate radiation-induced G1 arrest.,AIMed.d212.s1842
1064,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921
1065,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921
1066,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921
1067,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921
1068,AIMed.d221,True,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921
1069,AIMed.d221,False,A region of the beta subunit of the interferon alpha receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state.,AIMed.d221.s1921
1070,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922
1071,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922
1072,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922
1073,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922
1074,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922
1075,AIMed.d221,False,Coexpression of the alpha and betaL subunits of the human interferon alpha (IFNalpha) receptor is required for the induction of an antiviral state by human IFNalpha.,AIMed.d221.s1922
1076,AIMed.d221,False,Our results demonstrated that the first 82 amino acids (AAs) (AAs 265-346) of the cytoplasmic domain of the betaL chain are sufficient to activate the Jak-Stat pathway and trigger an antiviral state after IFNalpha2 binding to the receptor.,AIMed.d221.s1924
1077,AIMed.d221,False,"This region of the betaL chain, required for Jak1 binding and activation, contains the Box 1 motif that is important for the interaction of some cytokine receptors with Jak kinases.",AIMed.d221.s1925
1078,AIMed.d223,True,"Interaction between cell cycle regulator, E2F-1, and NF-kappaB mediates repression of HIV-1 gene transcription.",AIMed.d223.s1934
1079,AIMed.d223,False,The NF-kappaB/Rel family of transcription factors is one of the main targets of cytokines and other agents that induce HIV-1 gene expression.,AIMed.d223.s1935
1080,AIMed.d223,True,Some of these extracellular stimuli arrest cells in the G1 phase of the mitotic division cycle and modulate the activity of the tumor suppressor protein Rb and its partner E2F-1.,AIMed.d223.s1936
1081,AIMed.d223,True,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938
1082,AIMed.d223,True,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938
1083,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938
1084,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938
1085,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938
1086,AIMed.d223,False,"Here, we demonstrate that E2F-1 may regulate the activity of the HIV-1 long terminal repeat through its ability to bind sequences in the NF-kappaB enhancer region and to interact with the NF-kappaB subunit, p50.",AIMed.d223.s1938
1087,AIMed.d223,False,Gel retardation and methylation interference assays show that E2F-1 is able to bind specifically to a site embedded within the two NF-kappaB elements.,AIMed.d223.s1939
1088,AIMed.d223,False,Gel retardation/immunoblot analysis using purified E2F-1 and p50 homodimers reveals the presence of complexes containing both proteins.,AIMed.d223.s1940
1089,AIMed.d223,True,Affinity chromatography and co-immunoprecipitation assays provide evidence for direct interaction of E2F-1 and p50 in the absence of their DNA target sequences.,AIMed.d223.s1941
1090,AIMed.d223,False,In vitro transcription assay demonstrates that E2F-1 represses NF-kappaB mediated transcription in a cell-free system.,AIMed.d223.s1942
1091,AIMed.d223,False,"Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.",AIMed.d223.s1943
1092,AIMed.d223,False,"Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.",AIMed.d223.s1943
1093,AIMed.d223,False,"Functional studies in Jurkat T lymphocytic cells point to the importance of both the E2F and NF-kappaB binding sites in E2F-1 mediated repression of HIV-1 promoter, in vivo.",AIMed.d223.s1943
1094,AIMed.d223,True,"The results of this study suggest that NF-kappaB activity may be regulated by its interaction with the cell cycle regulatory protein, E2F-1.",AIMed.d223.s1944
